Bevacizumab for recurrent, persistent or advanced cervical cancer: reproducibility of GOG 240 study results in “real world” patients
-
A. Godoy-Ortiz [2] ; Y. Plata [3] ; J. Alcaide [1] ; A. Galeote [2] ; B. Pajares [2] ; E. Saez [2] ; E. Alba [2] ; A. Sánchez-Muñoz [2]
-
[1] Hospital Costa Del Sol
Hospital Costa Del Sol
Marbella, España
-
[2] Hospital Universitario Regional Málaga, España
-
[3] Complejo Hospitalario de Jaén, España
-
- Localización: Clinical & translational oncology, ISSN 1699-048X, Vol. 20, Nº. 7 (July 2018), 2018, págs. 922-927
- Idioma: inglés
- Texto completo no disponible (Saber más ...)
-
Resumen
Purpose Bevacizumab is the only therapeutic target approved for patients with persistent, recurrent or advanced cervical cancer from a phase III study that combined with chemotherapy; it proves a significant increase in overall survival. To retrospectively assess the efficacy and safety of bevacizumab as the first-line treatment in patients from usual clinical practice with recurrent/persistent or advanced cervical cancer.
Patients and methods Treatment consisted of cisplatin 50 mg/m2 or carboplatin AUC 5 plus paclitaxel 175 mg/m2 for 6–8 cycles and bevacizumab 15 mg/kg every 3 weeks up to progression or unacceptable toxicity. The endpoints were progression-free survival (PFS), overall survival (OS), response rates (RR) and toxicity.
Results Twenty-seven patients were included from January 2014 to June 2017, with a median follow-up 10, 1 months. Eleven percent had recurrent/persistent disease and 89% had metastatic disease at diagnosis. The prior exposition to platinum was 70%. The median PFS and OS were 9, 6 and 21, 5 months, respectively. There was an increase of fistula formation (22%). All of them had pelvic and peritoneal disease at the beginning of treatment and previous treatment with chemoradiotherapy; non-incidence differences were found according to the type of platinum agent used. There were two treatment-related deaths, one from intestinal perforation and another from severe sepsis.
Conclusion Finally, although our study does have certain limitations, we believe that it can provide useful information and encouraging evidence that the routine use of bevacizumab as part of first-line treatment of patients with advanced cervical cancer may be associated with outcomes comparable with those obtained in GOG240 study.
